Corcept Therapeutics has shown unexpected KORLYM franchise durability despite generic pressure and legal headwinds. Relacorilant's transition plan faltered after an FDA CRL, delaying lifecycle ...

REDWOOD CITY, Calif., December 31, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...

The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials showing efficacy. Outlook Therapeutics remains committed to U.S. approval and ...

A local man set out to make Christmas special for those who might not experience the magic otherwise. Using his lived experiences, he is helping area homeless people one kind gesture at a time.

Sanofi SNY announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking approval for its investigational Bruton's tyrosine kinase (BTK) inhibitor, ...